Better Performances and Objective Interpretation of Results with ReaScan STREP A Rapid Test

A recent publication on the European Infectious Disease journal, highlights the extremely good performance of ReaScan® STREP A rapid test.

European Infectious Disease is a peer-reviewed bi-annual journal comprising review articles, case reports, practice guides, theoretical discussions, and original research.

It features balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the field of infectious disease.

Abstract
ReaScan® STREP A is a novel rapid test for Streptococcus pyogenes (Group A Streptococcus [GAS]), which is a common cause of curable tonsillitis and pharyngitis.

ReaScan Strep A is suitable for point-of-care testing for GAS with minimum training, and its performance is comparable to a standard laboratory method for GAS.

The test performance was compared with streptococcal culture and with a commercial antigen test in parallel throat swab samples. ReaScan Strep A test performed in good concordance with the culture, showing sensitivity 92.1 % and specificity 96.9 %, as well as positive predictive value (PPV) 85.4 % and negative predictive value (NPV) 98.4 %, with a prevalence of 16.5 %. The corresponding values for a commercial antigen test were somewhat lower; still, the difference was not statistically significant.